Showing results (231-240 of 742) with videos related to

Sort By:
Pageof 75
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2026
Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN)Uday Yanamandra, Raja Ramachandran, Vinay Sakhuja, et al.
Blood Cancer Journal|May 15, 2023
Conditional survival in multiple myeloma and impact of prognostic factors over timeNadine H Abdallah, Alexandra N Smith, Susan Geyer, et al.
Blood Cancer Journal|August 7, 2025
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresisElham Askari, Angela Dispenzieri, Francis K Buadi, et al.
American Journal of Hematology|February 10, 2017
Hematology patient reported symptom screen to assess quality of life for AL amyloidosisRahma Warsame, Shaji K Kumar, Morie A Gertz, et al.
Blood Advances|November 13, 2024
Retreatment of multiple myeloma with previously refractory drugsUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 24, 2019
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosisEli Muchtar, Angela Dispenzieri, Dragan Jevremovic, et al.
Leukemia|October 17, 2018
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapseSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Pageof 75